Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Passmore

Showing results (121-130 of 134) with videos related to

Pageof 14
Sort By:
Plos One|June 30, 2017
Core outcome measures for interventions to prevent or slow the progress of dementia for people living with mild to moderate dementia: Systematic review and consensus recommendationsLucy Webster, Derek Groskreutz, Anna Grinbergs-Saull, et al.
Trials|April 5, 2019
Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study)Grazia Daniela Femminella, Eleni Frangou, Sharon B Love, et al.
Trials|July 21, 2020
Correction to: Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study)Grazia Daniela Femminella, Eleni Frangou, Sharon B Love, et al.
Plos One|July 9, 2019
Gene-based analysis in HRC imputed genome wide association data identifies three novel genes for Alzheimer's diseaseEmily Baker, Rebecca Sims, Ganna Leonenko, et al.
Health Technology Assessment (Winchester, England)|June 20, 2017
Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendationsLucy Webster, Derek Groskreutz, Anna Grinbergs-Saull, et al.
Alzheimer'S Research & Therapy|February 18, 2021
Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer's subjects?Grazia Daniela Femminella, Nicholas R Livingston, Sanara Raza, et al.
Nature Medicine|December 1, 2025
Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trialPaul Edison, Grazia Daniela Femminella, Craig Ritchie, et al.
Plos One|January 26, 2010
Concordant association of insulin degrading enzyme gene (IDE) variants with IDE mRNA, Abeta, and Alzheimer's diseaseMinerva M Carrasquillo, Olivia Belbin, Fanggeng Zou, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 16, 2019
Vascular dysfunction-The disregarded partner of Alzheimer's diseaseMelanie D Sweeney, Axel Montagne, Abhay P Sagare, et al.
Plos One|June 13, 2014
Gene-wide analysis detects two new susceptibility genes for Alzheimer's diseaseValentina Escott-Price, Céline Bellenguez, Li-San Wang, et al.
Pageof 14

Showing results (121-130 of 134) with videos related to

Sort By:
Pageof 14
Plos One|June 30, 2017
Core outcome measures for interventions to prevent or slow the progress of dementia for people living with mild to moderate dementia: Systematic review and consensus recommendationsLucy Webster, Derek Groskreutz, Anna Grinbergs-Saull, et al.
Trials|April 5, 2019
Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study)Grazia Daniela Femminella, Eleni Frangou, Sharon B Love, et al.
Trials|July 21, 2020
Correction to: Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study)Grazia Daniela Femminella, Eleni Frangou, Sharon B Love, et al.
Plos One|July 9, 2019
Gene-based analysis in HRC imputed genome wide association data identifies three novel genes for Alzheimer's diseaseEmily Baker, Rebecca Sims, Ganna Leonenko, et al.
Health Technology Assessment (Winchester, England)|June 20, 2017
Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendationsLucy Webster, Derek Groskreutz, Anna Grinbergs-Saull, et al.
Alzheimer'S Research & Therapy|February 18, 2021
Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer's subjects?Grazia Daniela Femminella, Nicholas R Livingston, Sanara Raza, et al.
Nature Medicine|December 1, 2025
Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trialPaul Edison, Grazia Daniela Femminella, Craig Ritchie, et al.
Plos One|January 26, 2010
Concordant association of insulin degrading enzyme gene (IDE) variants with IDE mRNA, Abeta, and Alzheimer's diseaseMinerva M Carrasquillo, Olivia Belbin, Fanggeng Zou, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 16, 2019
Vascular dysfunction-The disregarded partner of Alzheimer's diseaseMelanie D Sweeney, Axel Montagne, Abhay P Sagare, et al.
Plos One|June 13, 2014
Gene-wide analysis detects two new susceptibility genes for Alzheimer's diseaseValentina Escott-Price, Céline Bellenguez, Li-San Wang, et al.
Pageof 14